---
title: Treatment of SARS Caused by COVID-19 With Ruxolitinib
nct_id: NCT04334044
overall_status: COMPLETED
phase: PHASE1, PHASE2
sponsor: Grupo Cooperativo de Hemopatías Malignas
study_type: INTERVENTIONAL
primary_condition: COVID-19
countries: Mexico
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04334044.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04334044"
ct_last_update_post_date: 2021-07-07
last_seen_at: "2026-05-12T06:35:01.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Treatment of SARS Caused by COVID-19 With Ruxolitinib

**Official Title:** Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib

**NCT ID:** [NCT04334044](https://clinicaltrials.gov/study/NCT04334044)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 77
- **Lead Sponsor:** Grupo Cooperativo de Hemopatías Malignas
- **Conditions:** COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2
- **Start Date:** 2020-09-01
- **Completion Date:** 2021-04-30
- **CT.gov Last Update:** 2021-07-07

## Brief Summary

In December 2019, a new virus emerged in Wuhan, China rapidly becoming a pandemic with registered cases above 800,000 around the world. The virus is now known as SARS-CoV2 calling its disease coronavirus-19 or COVID-19. The mortality of the virus has been reported around 2-10% and its causes because of the proinflammatory immune response generated on the host. The cytokines involved in the immune response to COVID-19 are IL-1, IL-2, IL4, IL-6, IL-10, IL-12, IL-13, IL-17, GCSF, MCSF, IP-10, MCP-1, MIP-1α, HGF, IFN-γ y TNF-α.

Ruxolitinib is an inhibitor of JAK 1/2 which is responsable for multiple cellular signals including the proinflammatory IL-6. Ruxolitinib works as and immunomodulator decreasing the cytotoxic T lymphocytes and increasing the Treg cells.

This study is intended to stop the disregulated immune response caused by COVID-19 that generates the pneumonia and subsequent severe acute respiratory syndrome.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients with diagnosed COVID-19 with confirmatory test
* Increase in work of breathing or presence of dyspnea
* Presence of lung changes associated with COVID pneumonia by chest imaging
* Informed consent

Exclusion Criteria:

* Pregnancy or breastfeeding
* Thrombocytopenia below 20,000 cells/mm3
* Neutropenia below 500 cels/mm3
* Known and active infection of HIV, Hepatitis C, Hepatitis B, Herpes Zoster or Mycobacterium Tuberculosis
```

## Arms

- **Ruxolitinib** (EXPERIMENTAL) — Ruxolitinib 5 mg BID since the beginning of dyspnea or increment of work of breathing with pneumonia changes in chest CT-scan

## Interventions

- **Ruxolitinib Oral Tablet** (DRUG) — Ruxolitinib 5 mg twice a day

## Primary Outcomes

- **Recovery of Pneumonia** _(time frame: 14 days)_ — Presence of recovery of pneumonia characterized by cease of respiratory symptoms

## Secondary Outcomes

- **Response of C-reactive protein** _(time frame: 14 days)_
- **Response of Ferritin** _(time frame: 14 days)_
- **Response of D-dimer** _(time frame: 14 days)_
- **Rate of ICU admission** _(time frame: 14 days)_
- **Rate of mechanical ventilation** _(time frame: 14 days)_
- **Overall Survival** _(time frame: 1 month)_
- **Toxicity Rate** _(time frame: 1 month)_

## Locations (1)

- Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, State of Mexico, Mexico

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.grupo cooperativo de hemopatías malignas|huixquilucan|state of mexico|mexico` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04334044.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04334044*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*